The mechanisms through which anti-PD-1/PD-L1 ICBs treat cancer cells include increasing tumour-infiltrating T cells that produce inflammatory mediators, such as IFNs, and inducing cytotoxicity of CD8+ T cells to kill tumour cells [10]. The gene discussed is PDCD1; the disease is neoplasm.